Update On Oral HCV Protease Inhibitor SCH 503034 Clinical Development Program For Hepatitis C

... Schering-Plough Corporation (NYSE: SGP) today reported that it has completed patient enrollment in the first part of its ongoing Phase II clinical study to determine the appropriate dose range of its investigational oral hepatitis C protease inhibitor (SCH 503034) capsules. SCH 503034 is being evaluated in a large Phase II study in combination with PEG-INTRON(R) (peginterferon alfa-2b) for the treatment of patients chronically infected with hepatitis C virus (HCV) genotype 1 who were nonresponders to peginterferon and ribavirin combination therapy... click link for more info. ...